IQVIA
This sponsor has funded 3 studies across 3 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 36240 | Ongoing | Registry to study factors that may impact COVID-19 occurrence and severity (CARE) | No | No |
| 43315 | Ongoing | DISPARITIES IN LUNG CANCER MANAGEMENT IN ITALY: A PUBLIC HEALTH STUDY | No | No |
| 49568 | Ongoing | An epidemiological investigation of high-risk children for Respiratory Syncytial Virus infections - RWE palivizumab utilization as a RSV preventive... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
IQVIA
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
IQVIA
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
IQVIA
3 Study countries specified are the following:
- Italy
- United Kingdom
- United States